Source details

F1000Research

Open Access ⓘ

Scopus coverage years: from 2012 to Present

Publisher: Taylor & Francis

E-ISSN: 2046-1402

Subject area: (Pharmacology, Toxicology and Pharmaceutics: General Pharmacology, Toxicology and Pharmaceutics)

(Immunology and Microbiology: General Immunology and Microbiology) View all ⌄

Source type: Journal

CiteScore 2022	ⓘ
3.6	
SJR 2022	ⓘ
0.871	
SNIP 2022	ⓘ
0.912	

[View all documents >] [Set document alert] 💾 Save to source list   Source Homepage

---

CiteScore   CiteScore rank & trend   Scopus content coverage

ⓘ Improved CiteScore methodology   ✕

CiteScore 2022 counts the citations received in 2019-2022 to articles, reviews, conference papers, book chapters and data papers published in 2019-2022, and divides this by the number of publications published in 2019-2022. Learn more >

CiteScore 2022 ⌄

$$3.6 = \frac{14{,}412 \text{ Citations } 2019 - 2022}{3{,}991 \text{ Documents } 2019 - 2022}$$

Calculated on 05 May, 2023

CiteScoreTracker 2023 ⓘ

$$5.0 = \frac{10{,}616 \text{ Citations to date}}{2{,}138 \text{ Documents to date}}$$

Last updated on 05 October, 2023 • Updated monthly

CiteScore rank 2022 ⓘ

Category	Rank	Percentile
Pharmacology, Toxicology and Pharmaceutics	#24/79	70th
└ General Pharmacology, Toxicology and Pharmaceutics		
Immunology and Microbiology	#22/53	59th

View CiteScore methodology >   CiteScore FAQ >   Add CiteScore to your site 🔗

Scimago Jou Enter Journal Title, ISSN or Publisher Name

Home   Journal Rankings   Country Rankings   Viz Tools   Help   About Us

F1000Research 🔓

COUNTRY	SUBJECT AREA AND CATEGORY	PUBLISHER	H-INDEX
United Kingdom	Biochemistry, Genetics and Molecular Biology		**88**

COUNTRY

United Kingdom

Universities and research institutions in United Kingdom

Media Ranking in United Kingdom

SUBJECT AREA AND CATEGORY

Biochemistry, Genetics and Molecular Biology
  Biochemistry, Genetics and Molecular Biology (miscellaneous)

Immunology and Microbiology
  Immunology and Microbiology (miscellaneous)

Medicine
  Medicine (miscellaneous)

Pharmacology, Toxicology and Pharmaceutics
  Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

PUBLISHER

H-INDEX

88

PUBLICATION TYPE	ISSN	COVERAGE	INFORMATION
Journals	20461402	2012-2022	Homepage
			How to publish in this journal
			research@f1000.com

SCOPE

F1000Research publishes articles and other research outputs reporting basic scientific, scholarly, translational and clinical research across the physical and life sciences, engineering, medicine, social sciences and humanities. F1000Research is a scholarly publication platform set up for the scientific, scholarly and medical research community; each article has at least one author who is a qualified researcher, scholar or clinician actively working in their speciality and who has made a key contribution to the article. Articles must be original (not duplications). All research is suitable irrespective of the perceived level of interest or novelty; we welcome confirmatory and negative results, as well as null studies. F1000Research publishes different type of research, including clinical trials, systematic reviews, software tools, method articles, and many others. Reviews and Opinion articles providing a balanced and comprehensive overview of the latest discoveries in a particular field,

or presenting a personal perspective on recent developments, are also welcome. See the full list of article types we accept for more information.

Join the conversation about this journal

Quartiles

FIND SIMILAR JOURNALS ?

1	2	3	4
Advances in Experimental Medicine and Biology	**eBioMedicine**	**Science Translational Medicine**	**Frontiers of**
USA	NLD	USA	CHN
79%	**78%**	**73%**	7
similarity	similarity	similarity	si

SJR

Total Documents

Total Cites   Self-Cites

Citations per document

External Cites per Doc   Cites per Doc

% International Collaboration


Citable documents   Non-citable documents

Cited documents   Uncited documents

F1000Research

Q1   Medicine (miscellaneous)
      best quartile

SJR 2022
0.87

powered by scimagojr.com

← Show this widget in your own website

Just copy the code below and paste within your html code:

<a href="https://www.scimag

SCImago Graphica

Explore, visually communicate and make sense of data with our **new data visualization tool**.

Metrics based on Scopus® data as of April 2023

C   **Carlos Luna**   2 weeks ago

¿La revista acepta publicar atículos científicos en temáticas relacionadas con la gestión pública?

reply

SCImago Team

Melanie Ortiz   2 weeks ago

Dear Carlos,
Thank you for contacting us.

You searched for soebagijo adi

ARTICLES   FACULTY REVIEWS   DOCUMENTS   POSTERS   SLIDES

◄

FILTERS ⌄   1-2 of 2 ARTICLES

RESEARCH ARTICLE 📊 metrics   ✔ ?

REVISED   **The performance of lipid profiles and ratios as a predictor of arterial stiffness measured by brachial-ankle pulse wave velocity in type 2 diabetic patients [version 2; peer review: 1 approved, 1 approved with reservations]**

Soebagijo Adi Soelistijo, Robert Dwitama Adiwinoto, Agung Pranoto, Deasy Ardiany

👥 *PEER REVIEWERS* Martin Haluzík; Agata Stanek

LATEST VERSION PUBLISHED 05 Jun 2023

CASE REPORT 📊 metrics   ✔ ✔

REVISED   **Case Report: Diabetic nephropathy aggravates the progression and prognosis of COVID-19-associated acute limb ischemia [version 2; peer review: 2 approved]**

Decsa M. Hertanto, Henry Sutanto, Soebagijo Adi

👥 *PEER REVIEWERS* Ketut Suastika; Joyce Bernardi

LATEST VERSION PUBLISHED 17 Sep 2021

PUBLISH YOUR RESEARCH

📄 **ARTICLES**

We publish a wide range of article types in science, engineering, medicine, social sciences and humanities, with no editorial biases.

SUBMIT AN ARTICLE (/FOR-AUTHORS/PUBLISH-YOUR-RESEARCH)

See guidelines and policies.

An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.

BROWSE   CONTACT
GATEWAYS   COOKIE NOTICE
COLLECTIONS   PRIVACY NOTICE
HOW IT WORKS   RSS
BLOG

Advisory Board

The Advisory Board of F1000Research comprises a large group of leading experts across biology and medicine. They do not act as Editors in the traditional sense (they do not handle manuscripts or make decisions to accept or reject a paper), but they provide strategic input on the direction we should take with F1000Research. They occasionally advise us on issues arising with specific articles, and many members of the board also review for us.

A B C D E F G H I J K L M N O P R S T U V W X Y Z

B

Ian Beales
Nelson Bennett
Avri Ben-Ze'ev
Benedikt Berninger
Eric Beyer
Azra Bihorac
Daniel Bikle
Kevin J Black
Chellakkan Selvanesan Blesson
Erin Aiello Bowles
Bruce Brew

C

David Catcheside
Andrew Chalmers
Tak Mao Chan
Karen Chapman
Declan Chard
Walter Chazin
Jonathan Chernoff
Cheng-Ming Chiang
Ryan Chisholm
Wei-Sheng Chong
Sandra Citi
Vitaly Citovsky
Tim Clark
James Coker
Giuseppe Colloca
William Colmers
Jason Crawford
David Criddle

D

Ira Daar
Linda Dagi
Blossom Damania
Eric Dannaoui
Vinicio de Jesus Perez
Sharon DeMorrow
Gonzalo G de Polavieja
Saskia de Wildt
Harriet de Wit
Eleftherios P Diamandis
Phedias Diamandis
Betty Diamond
J Alan Diehl
Petya Dimitrova
Annette Dolphin
Lucy Donaldson
Sylvie Doublié
Paschalis-Thoma Doulias
Crislyn D'Souza-Schorey
James Duffin
Janice Du Mont

E

Sharyn Endow
Markus Engstler
Sam Enna
Erim Erdem

F

Alastair Ferguson
Gerardo Ferrara
Richard Festenstein
Thomas Finger
Céline Fiset
Heike Fölsch
Steven Frank
Bernd Fritzsch

Ivan Gerling
Carole Goble
Richard Gomer
Andrew Goryachev
John Greenspan
Guy Griebel
W Sue Griffin
Elizabeth Grove
Jaime Grutzendler
Wei Guo

John Lee
Laurel Lenz
Simon Levin
Stefan Linder
Ton Lisman
Creighton M Litton
Hartmut Lode
Theresa Lu
Robyn Lucas
Ben Lugtenberg
Paul Lyons

H
Adam Hartman
Johannes Hell
Winston Hide
Stephen Hoffman
Stephen Holgate
Thorsten Hoppe
Wolfgang Huber
Arthur Hurwitz

M
Roberto Maggi
Martin Marinus
M Rashad Massoud
Jocelyn McDonald
Robert McPeek
Anthony Means
Julien Mendlewicz
Arthur Mercurio
Ralph Mistlberger
Ali Mobasheri
David Moher
Randall Moon
Carlos Morel
Dimitrios Morikis
Nicola Mulder

I
Radu Iliescu
Robert Insall
Harry Ischiropoulos

J
Jan Jakobsson
Guilhem Janbon
Michael Joannidis
Norman Johnson
Etienne Joly

N
Corey Nislow

O
Chiadi Onyike

K
Dieter Kabelitz
Wael Kafienah
Chaya Kalcheim
Lynn Kamerlin
Mikhail Kazachkov
Johannes S Kern
Jean-Pierre Kinet
Edward Kipreos
Fenella Kirkham
Gordon Klein
Alisa Koch
Amos Korczyn
Benoit Kornmann
Jan Kucera
Anuj Kumar
Saravana Kumar

P
Leonid Padyukov
Eleftherios Paschalis
Graham Pawelec
Ming Pei
Giampaolo Perna
Stephen Pinfield
Michel Pohl
Simon Portsmouth
David Potter
Chaim Putterman

José Luis Riechmann
Karin Romisch
Vincent Rotello
Barry Rouse
Gloria Rudenko
James Russell

S

Philippe Saas
Paul R Sanberg
Alan Schechter
Werner Scheithauer
Tamar Schlick
Thomas Schnider
Alfons Schnitzler
Irene Schulz
Michael Sendtner
Andrew D Sharrocks
Nilabh Shastri
Kazim Sheikh
Andrew Shennan
Xiao Shifu
Chiara Simonelli
Helmy Siragy
Cassian Sitaru
Richard Smith
H Peter Soyer
Pamela Stanley
Christoph Stein
Carly Stevens
Charles Stevens
Bruno Stieger

T

Paul-Peter Tak
Paul Terry
Igor Tetko
Jacques Thibodeau
Jakub Tolar
Peter Tonellato
Francis Tsai
Takeshi Tsubata
Tom Tullius
Burkhard Tümmler

V

Hans van Beek
Hans van Bokhoven
Martin van den Berg
Peter Van Endert
Dirk van Helden
Chandra Verma
Jan Vermorken
David Voehringer

W

Claire Walczak
Nick Ward
Peter Wark
Stephen Waxman
Alan Wein
Tom Woodcock
Long-Jun Wu
Jeremy C Wyatt
Kevan Wylie

X

Yongbiao Xue

Y

Michael B Yaffe
Kenneth Yamada
Helen Yap
Dorothy Yuan

Z

Yunde Zhao
Deyou Zheng
Guy Zimmerman
Christos Zouboulis

Check for updates

RESEARCH ARTICLE

REVISED **The performance of lipid profiles and ratios as a predictor of arterial stiffness measured by brachial-ankle pulse wave velocity in type 2 diabetic patients** [version 2; peer review: 1 approved, 1 approved with reservations]

Soebagijo Adi Soelistijo[1], Robert Dwitama Adiwinoto 🔟[2], Agung Pranoto[1], Deasy Ardiany[1]

[1]Division of Endocrinology, Diabetes, and Metabolism, Department of Internal Medicine, Airlangga University Faculty of Medicine, Dr. Soetomo Academic Teaching Hospital, Surabaya, 60132, Indonesia
[2]Department of Internal Medicine, Airlangga University Faculty of Medicine, Dr. Soetomo Academic Teaching Hospital, Surabaya, 60132, Indonesia

Abstract

Background: Early identification of arterial stiffness in Type 2 diabetes mellitus (T2DM) patients before the manifestation of atherosclerosis would be clinically beneficial. Our study aimed to explore the correlation of lipid profiles and ratios with arterial stiffness, and construct a predictive model for arterial stiffness in T2DM patients using those parameters.

Methods: One hundred and eighty-four adult T2DM patients in the diabetes outpatient clinic at the Dr. Soetomo general academic hospital were enrolled in this cross-sectional study in 2015 and 2019. Sociodemographic, glycosylated hemoglobin (HbA1c), lipid profiles, and brachial-ankle pulse wave velocity (ba-PWV) data were collected from all subjects. The subjects were divided into a group with arterial stiffness (ba-PWV > 18 m/sec) and without arterial stiffness (ba-PWV ≤ 18 m/sec). A correlation test was used to evaluate the association, and receiver operator characteristics (ROC) curves analysis were used to determine the cut-off value, sensitivity, and specificity. The risk analysis model was calculated using bivariate logistic regression analysis.

Results: The group with arterial stiffness had higher lipid profiles: total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and lipid ratios. A significant positive correlation was found between TC, TG, LDL-C, and all lipid ratios with ba-PWV. A negative correlation was found between HDL-C and ba-PWV. All lipid ratio parameters can be used as predictors of arterial stiffness, especially non-HDL-C with cut-

Open Peer Review

Approval Status ✔ ❓

	1	2
version 2 (revision) 05 Jun 2023		
version 1 23 Dec 2022	✔ view	❓ view

1. **Martin Haluzík**, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

2. **Agata Stanek** 🔟, Medical University of Silesia, Bytom, Poland

Any reports and responses or comments on the article can be found at the end of the article.

off value: 150 mg/dL (sensitivity 96.8% and specificity 52.9%) and TG/HDL-C ratio with cut-off value: 4.51 (sensitivity 81.0% and specificity 74.2%). Elevated TG/HDL-C ratio and non-HDL-C displayed higher risk (OR: 12.293 and 16.312; $p < 0.05$) of having arterial stiffness compared to other lipid ratios.

Conclusions: Lipid profiles and lipid ratios, especially TG/HDL-C ratio and non-HDL-C, are potential biochemical markers for arterial stiffness in T2DM patients.

Keywords
dyslipidemia, arterial stiffness, cardiovascular disease, risk, type 2 diabetes mellitus

Corresponding authors: Soebagijo Adi Soelistijo (soebagijo.adi.s@fk.unair.ac.id), Robert Dwitama Adiwinoto (dr.robert.dwi@gmail.com)

Author roles: Soelistijo SA: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Resources, Software, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Adiwinoto RD**: Conceptualization, Data Curation, Formal Analysis, Methodology, Project Administration, Resources, Software, Writing – Original Draft Preparation, Writing – Review & Editing; **Pranoto A**: Conceptualization, Data Curation, Formal Analysis, Methodology, Resources, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Ardiany D**: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Resources, Software, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing

Introduction

Type 2 diabetes mellitus (T2DM) is a major health concern and prevalence is increasing worldwide. More than 460 million people are already affected, or 9.3% of the global population, and there are projected to be around 578 million cases by 2030. Indonesia is among the top ten countries with the most prevalent occurrence of diabetes, estimated to be around 10.7 million cases in 2019 and projected to increase to 13.7 million in 2030 and to 16.6 million in 2045.[1,2] The consequence of the growing rates of T2DM is the increase in diabetes-related complications, especially macrovascular and microvascular. The prevalence of macrovascular and microvascular complications was estimated to be 27.2% and 53.5%, respectively.[3] However, cardiovascular disease (CVD) remains the leading cause of morbidity and mortality in T2DM patients.[4] The economic impact of T2DM regarding the medical care costs and the indirect costs due to decreased productivity associated with diabetes-related morbidity is also significant.[5]

Coronary artery disease, peripheral artery disease (PAD), heart failure, and cerebral infarction are the typical manifestations of atherosclerotic CVD (ASCVD) in T2DM. Abnormal lipid metabolism (dyslipidemia) is the main pathogenesis for the development of ASCVD; meanwhile dyslipidemia is common in T2DM patients, affecting 60–70% of T2DM.[6] The association between cholesterol and the cardiovascular outcome is well established. Recently, many risk factors for CVD have been published in international studies, implying more complex lipoprotein disorders in atherosclerosis development. Lipid ratios (TC/HDL-C, TG/HDL-C, and LDL-C/HDL-C) application, in terms of cardiovascular risk stratification and lipid-lowering therapy efficacy assessment, are promising options. Besides the advantage of being practical in clinical settings, changes in these ratios have indicated better measures of the reduction in cardiovascular risk compared with the conventional lipid parameters.[7]

Arterial stiffening depicts degenerative changes of the extracellular matrix (ECM) in the arterial media layer, marked with collagen deposition, cross-linking, and elastin fatigue fracture. From a pathological perspective, arterial stiffening is different from atherosclerosis. However, both processes commonly occur in the same vascular area, are part of the vascular aging process, and share the same risk factors. Moreover, several clinical studies have reported a significant association between arterial stiffness and the degree of atherosclerosis and also with the risk of cardiovascular event incidents.[8] Early recognition of arterial stiffness in the high-risk population, such as T2DM, before the manifestation of clinical ASCVD, is substantially beneficial.[9] Carotid-femoral pulse wave velocity (cf-PWV) represents primarily the aortic stiffness and is considered the gold standard for arterial stiffness measurement.[10] Nowadays, ba-PWV has been widely used in clinical settings and it has strong positive association with cf-PWV. Because ba-PWV is easier to obtain and more convenient for patients, it could serve as an alternative to cf-PWV measurement.[11,12]

Serum HDL-C, in the middle-aged and elderly population, has been associated with protection against arterial stiffness. Previous studies have also investigated the degree of association between a single atherogenic lipid parameter or ratio (the LDL-C, TG/HDL-C, and non HDL-C) with arterial stiffness. However, each of those studies claimed some lipid parameters or ratios superior to one another.[9] Furthermore, the data regarding the use of those lipid ratios as a predictive biochemical marker for arterial stiffness in T2DM are lacking, especially in the Indonesian population.

Objectives

Therefore, this study aimed to explore the correlation of lipid profiles and ratios with arterial stiffness, construct a predictive model for arterial stiffness in T2DM patients, and ultimately analyze the performance (sensitivity and specificity) of the lipid ratios to detect arterial stiffness in T2DM patients.

Methods

Ethical considerations

This study was approved by the ethical committee of Dr. Soetomo General Academic Hospital, Surabaya, Indonesia: 316/Panke.KKE/V/2015 (May 29th, 2015) and 1311/KEPK/V/2019 (July 20th, 2019). After receiving an explanation from the researchers about the research procedure, all eligible subjects gave written informed consent.

Study design and setting

This was a cross-sectional design study conducted in the Endocrinology and Diabetes outpatient clinic at the Dr. Soetomo General Academic Hospital in Surabaya, Indonesia, during February–May 2016 and September–November 2019.

Participants

The sample size of this study was calculated using the following formula to determine the minimum sample needed.

$$n = \left[\frac{(Z\alpha + Z\beta)}{0.5 \ln \frac{1+r}{1-r}} \right]^2 + 3$$

Significance = 95%; power = 80%; correlation coefficient = 0.217 from previous study.[9] Therefore, the minimum number of subjects for this study was 165. The subjects were recruited consecutively according to the inclusion and exclusion criteria. The inclusion criteria were adult patients (over 18 years of age) who had been diagnosed with T2DM. The exclusion criteria were current smoker, end-stage, or chronic kidney disease (CKD), subjects with active infection, known PAD, and subjects with a recent history of cerebral infarction (within 30 days).

Study variables

The dependent variable was arterial stiffness measured by ba-PWV. The independent variables were lipid profiles (total cholesterol, triglyceride, HDL-C, LDL-C, and non-HDL-C) and lipid ratios (TC/HDL-C, TG/HDL-C, and LDL-C/HDL-C).

Data collection

All participants were subjected to complete history, physical examination, and ba-PWV measurement. Lipid profiles and HbA1c data were obtained from the recent blood biochemistry examination in the last three months from the medical record, should the data be available. Otherwise, a venous blood sample was collected and sent to the laboratory of Dr. Soetomo General Academic Hospital in Surabaya, Indonesia for biochemical analysis. Metabolic syndrome was defined according to the latest criteria.[13] The TC/HDL-C is the ratio of the value of TC levels divided with HDL-C levels. The TG/HDL-C ratio is the result of the value of TG levels divided with HDL-C levels. The LDL-C/HDL-C ratio is the result of the value of LDL-C levels divided with HDL-C levels. The Non-HDL cholesterol value was calculated from HDL-C subtracted with TC levels.[14]

Brachial-ankle pulse wave velocity measurement

Pulse wave velocity is calculated from the ratio of the distance between two measurement points divided by the time required for the pressure wave to travel the distance. The travel distance was defined as the measurement from the center of the brachial cuff to the center of the ankle cuff. The pulse transit time (PTT) was obtained from two peak points of the diastolic pulse wave.[8,12] Brachial-ankle pulse wave velocity measurement was carried out using Va-Sera VS-1000 (Fukuda Denshi, Tokyo, Japan). The arterial stiffness measurement was carried out in a separate room with a cool temperature, quiet, and comfortable surrounding. Before the examination, the subjects were asked to remove any clothing and metal jewelry, then rested in a supine position for at least 15 minutes.[15] During the measurement, the subjects were not allowed to talk or move. The cut-off value of ba-PWV to define arterial stiffness is 18 m/sec.[16]

Statistical analysis

Data were analyzed using SPSS version 22.0 for Windows (IBM Corporation, New York, USA). Descriptive statistics for data that were normally distributed were expressed using mean and standard deviation, otherwise median and minimum maximum were used. An independent t-test or Mann–Whitney U-test was used to detect differences in lipid profile and lipid ratio values between groups with and without arterial stiffness. The correlation between HbA1c levels, lipid profiles, and lipid ratios with arterial stiffness was evaluated using Pearson or Spearman correlation test. Analysis of receiver operating characteristic curves (ROC) were used to determine the cut-off value, sensitivity, and specificity for each lipid ratio for arterial stiffness. Finally, bivariate logistic regression analysis was used to estimate risk prediction of lipid ratios against arterial stiffness in T2DM. Statistical significance was considered at p value < 0.05 and 95% confidence interval (CI).

Results

Subject characteristics

A total of 184 T2DM patients matched the inclusion criteria.[17] There were no significant differences in the socio-demographic (age and sex) and clinical (hypertension and obesity) characteristics between groups with and without arterial stiffness ($p > 0.05$). The HbA1c levels in the group with arterial stiffness appeared to be higher than the group without arterial stiffness and the difference was significant ($p = 0.038$). The lipid profile result was significantly higher in the group with arterial stiffness ($p < 0.05$) except for the LDL-C levels ($p = 0.261$). The HDL-C levels were significantly lower in the group with arterial stiffness compared to the group without arterial stiffness ($p < 0.05$). Lipid ratio findings were also significantly higher in the group with arterial stiffness. The comparison is presented in Table 1.

Correlation of lipid profiles and lipid ratios with ba-PWV

The Spearman correlation test was used to evaluate the correlation between HbA1c, lipid profiles and lipid ratios with ba-PWV values since the ba-PWV values were not normally distributed. We did not find a significant correlation between HbA1c and ba-PWV ($p > 0.05$). The lipid profiles and lipid ratios were significantly correlated with ba-PWV ($p < 0.05$) with various degrees of correlation. A negative correlation was found between HDL-C levels and ba-PWV values ($\rho = -0.221$) implying an inverse correlation. Lipid profiles (TC, TG, HDL-C, and LDL-C) had a weak correlation with ba-PWV when used alone. However, an increase in the correlation coefficient was observed when used as lipid ratios (TC/HDL-C, TG/HDL-C, LDL-C/HDL-C, and non HDL-C). The TC/HDL-C ratio demonstrated a moderate correlation ($\rho = 0.419$) among other lipid ratios. The correlation is described in Table 2.

Table 1. Comparison of demographic characteristics, obesity, glycemic control, lipid profile, and lipid ratios between groups with and without arterial stiffness.

Characteristics	Arterial stiffness present (baPWV > 18 m/s) n = 31	Arterial stiffness absent (baPWV ≤ 18 m/s) n = 153	p
Age (years), median (min–max)	63 (40–71)	57 (18–77)	0.186
Sex (n, %)			0.938
Male	13 (17.1%)	63 (82.9%)	
Female	18 (16.67%)	90 (83.33%)	
Hypertension (n, %)			0.558
Yes	19 (18.27%)	85 (81.73%)	
No	12 (15%)	68 (85%)	
Obese (n, %)			0.483
Yes	7 (13.72%)	44 (86.28%)	
No	24 (18.04%)	109 (81.96%)	
Metabolic syndrome (n, %)			0.040*
Yes	19 (23.17%)	63 (76.83%)	
No	12 (11.76%)	90 (88.24%)	
HbA1c (%), median (min–max)	8.4 (6.2–12.5)	7.6 (5.2–12.1)	0.038*
Total cholesterol (mg/dL), median (min–max)	212 (160–300)	197 (100–350)	0.000*
Triglyceride (mg/dL), median (min–max)	190 (91–380)	141 (38–412)	0.000*
HDL-C (mg/dL), median (min–max)	42 (28–82)	47 (29–157)	0.005*
LDL-C (mg/dL) (mean±SD)	141.29±31.04	132.59±40.64	0.261
Lipid ratios			
TC/HDL-C (mean±SD)	5.41±1.3	4.14±1.19	0.000*
TG/HDL-C (mean±SD)	4.8±1.58	3.26±1.69	0.000*
LDL-C/HDL-C (mean±SD)	3.41±1.02	2.84±1.1	0.008*
Non HDL-C (mean±SD)	181.29±29.76	146.77±42.13	0.000*

baPWV: brachial-ankle pulse wave velocity, HbA1c: glycosylated hemoglobin, HDL-C: high-density lipoprotein, LDL-C: low-density lipoprotein, TC: total cholesterol; TG: triglyceride.
*Significant ($p < 0.05$).

Table 2. Correlation of glycemic control, lipid profile, and lipid ratios with brachial-ankle pulse wave velocity.

Parameter	ρ	p
HbA1c (%)	0.048	0.515
Total cholesterol (mg/dL)	0.292	0.000*
Triglyceride (mg/dL)	0.239	0.001*
HDL-C (mg/dL)	-0.221	0.003*
LDL-C (mg/dL)	0.166	0.024*
TC/HDL-C	0.419	0.000*
TG/HDL-C	0.326	0.000*
LDL-C/HDL-C	0.281	0.000*
Non HDL-C	0.371	0.000*

HbA1c: glycosylated hemoglobin, HDL-C: high-density lipoprotein, LDL-C: low-density lipoprotein, TC: total cholesterol, TG: triglyceride.
Spearman correlation test was used.
*Significant ($p < 0.05$).

Model of lipid ratios as predictive markers for arterial stiffness in type 2 diabetes mellitus

An ROC analysis was applied for lipid ratios to arterial stiffness as the outcome of this study (Figure 1). Overall lipid ratios TC/HDL-C, TG/HDL-C, and non-HDL-C had a good performance to be used as predictive models (AUC > 0.7), except for LDL-C/HDL-C. Non-HDL-C had a sensitivity of 96.8% for arterial stiffness; however, the specificity was


Diagonal segments are produced by ties.

Figure 1. Receiver operator characteristics curve analysis of lipid ratios as a predictor of arterial stiffness in type 2 diabetes mellitus.

Table 3. Characteristics of lipid ratios using the optimal cut-off value to detect the presence of arterial stiffness in type 2 diabetes mellitus.

Parameter	AUC	95% CI	Cut-off value	Sensitivity	Specificity	p
TC/HDL-C	0.769	0.682–0.856	4.63	77.4%	68.6%	0.000*
TG/HDL-C	0.776	0.688–0.863	4.51	74.2%	81.0%	0.000*
LDL-C/HDL-C	0.644	0.544–0.744	2.71	83.9%	46.4%	0.012*
Non HDL-C	0.753	0.679–0.827	150	96.8	52.9%	0.000*

AUC: area under the curve, CI: confidence interval, HDL-C: high-density lipoprotein, LDL-C: low-density lipoprotein, TC: total cholesterol, TG: triglyceride.
*Significant ($p < 0.05$).

Table 4. Binary logistic regression analysis model of lipid ratios for having arterial stiffness in type 2 diabetes mellitus.

Parameter	β	OR	95% CI	p
TC/HDL-C	1.677	5.347	2.291–12.478	0.000*
TG/HDL-C	2.509	12.293	4.996–30.247	0.000*
LDL-C/HDL-C	1.505	4.502	1.642–12.343	0.003*
Non HDL-C	2.792	16.312	3.760–70.780	0.000*

OR: odds ratio, CI: confidence interval, HDL-C: high-density lipoprotein, LDL-C: low-density lipoprotein, TC: total cholesterol, TG: triglyceride.
*Significant ($p < 0.05$).

52.9% with cut-off value 150 mg/dL. TG/HDL-C ratio had a specificity of 81.0% and sensitivity of 74.2% with cut-off value 4.51. The characteristics of the lipid ratios are presented in Table 3.

Risk analysis model of lipid ratios as predictor for arterial stiffness in type 2 diabetes mellitus

The cut-off value of each lipid ratio derived from the ROC curve was used to determine the presence of arterial stiffness. Values above the cut-off point were classified as elevated, while values below or equal to the cut-off point were classified as normal. All lipid ratios demonstrated significant association as a risk factor for arterial stiffness in T2DM patients through bivariate logistic regression analysis (OR > 1; $p < 0.05$). Elevated TG/HDL-C ratio and non-HDL-C displayed higher risk (OR 12.293 and 16.312) of having arterial stiffness compared to elevated TC/HDL-C or LDL-C/HDL-C ratio (OR 5.347 and 4.502). These associations remained significant even after adjusting for age, HbA1c, and the presence of metabolic syndrome. The risk analysis model of the lipid ratios is presented in Table 4.

Discussion

To our knowledge, our present study is the first to evaluate not only the correlation of lipid ratios with arterial stiffness in T2DM patients but also define the cut-off value of lipid ratios which might contribute new insight in managing dyslipidemia and CVD risk in T2DM. The main findings of our study were: 1) the lipid ratios were correlated with arterial stiffness; 2) the lipid ratios, especially TG/HDL-C ratio and non-HDL-C, had good sensitivity to detect arterial stiffness; 3) elevated TG/HDL-C ratio and non HDL-C levels increased the risk of having arterial stiffness in T2DM. These findings indicate that lipid ratios are independently associated with the risk of arterial stiffness in the T2DM population.

Atherosclerosis is the main pathogenesis of CVD; however, early atherosclerosis is asymptomatic, therefore the majority goes undetected in the early stages. Arterial stiffness is involved in these early stages of atherosclerosis. Even though the relationship between arterial stiffness and atherosclerosis is still unclear, the interaction between the two may involve several complex hemodynamic, mechanical, metabolic, and enzymatic pathways. The increase in arterial stiffness results in increased blood pressure which promotes arterial remodeling leading to atherosclerosis.[18] The increase in intra-luminal pressure also promotes atheroma formation and deposition of excessive collagen in arterial walls.[8] These mechanisms are even more pronounced in T2DM in which endothelial dysfunction, a pivotal event in the initiation of atherosclerosis, is accelerated by the presence of hyperglycemia and advanced glycation end products (AGEs).[19] Moreover, T2DM is characterized by abnormal metabolism of lipoprotein which contributes to the pathomechanism of atherosclerosis. Therefore, the detection of arterial stiffness in T2DM before the development of clinical ASCVD is crucial.

Dyslipidemia and DM commonly occur together, affecting 60–70% of people with T2DM. The pathophysiology of dyslipidemia in T2DM is complex, involving a different number of abnormalities. The key abnormality is the increased production of very low-density lipoprotein (VLDL) by the liver, which is commonly found as elevated TG levels. Elevated TG-rich lipoproteins will affect other lipoproteins and result in lower Apo A-I and HDL-C levels. Increased LDL-C association with CVD is well established in T2DM patients, as in the non-diabetic population. However, a significantly reduced LDL-C still carries residual CVD risk in T2DM.[20] Therefore, a new CVD risk predictor is needed, and lipoprotein ratios can provide a better picture of the complex metabolic and clinical interactions between conventional lipid profile parameters. This is consistent with our findings in which lipid ratios showed a higher correlation with ba-PWV compared to conventional lipid profile parameters alone.

In our study, a significant correlation between TG/HDL-C ratio and arterial stiffness were observed ($\rho = 0.326$). Moreover, the TG/HDL-C ratio of > 4.51 predicts arterial stiffness with a sensitivity of 74.2% and specificity of 81.0%. An elevated TG/HDL-C ratio also increased the risk for arterial stiffness (OR: 12.293; 95% CI: 4.996–30.247). These findings are consistent with the study conducted by Chen & Dai[21] and Zhao et al.[9] which found that TG/HDL-C ratio is positively correlated with ba-PWV, but the participants of those studies were not limited to T2DM patients. Elevated TG/HDL-C ratio is a feature of metabolic syndrome which is associated with insulin resistance and cardiometabolic risk. Insulin resistance states and chronic hyperinsulinemia induce the local activity of the renin-angiotensin-aldosterone system, followed by the expression of angiotensin II receptors in vascular tissue, resulting in vessel wall hypertrophy, fibrosis, and reduced arterial elasticity. Furthermore, insulin resistance is strongly associated with endothelial dysfunction, marked with an imbalance between nitric oxide (NO) and endothelin-1, two important determinants of arterial stiffness.[8,22]

Our present study found that non-HDL-C positively correlated with arterial stiffness, and non-HDL-C levels of >150 mg/dL predict arterial stiffness with a sensitivity of 96.8% and specificity of 52.9%. An elevated non-HDL-C level also increased the risk for arterial stiffness (OR: 16.312; 95% CI: 3.760–70.780). These findings are similar to previous studies by Bando et al.[23] and de Oliveira et al.[24] which reported that elevated non-HDL-C levels are associated with an increased risk of arterial stiffness. The latest evidence indicated that HDL-C determination alone has no predictive role; therefore, replacing the criteria of metabolic syndrome with that of non-HDL-C is more relevant.[13] Unlike LDL-C, the non-HDL-C represents the cholesterol content in all the atherogenic lipoproteins, namely: VLDL-C, intermediate-density lipoprotein cholesterol (IDL-C), and lipoprotein (a) cholesterol.[25] In T2DM patients, non-HDL-C levels emphasize the role of the TG-rich lipoproteins in the development of arterial stiffness. The TG-rich lipoproteins through the TG hydrolysis process by lipoprotein lipase (LPL) contribute to low-grade inflammation of the arterial wall.[26] Inflammation has a pivotal role in both arterial stiffening and atherosclerosis.[27] In an in vitro study, C-reactive protein (CRP) decreased endothelial NO synthase (NOS) secretion and activity, resulting in "functional" arterial stiffening. Furthermore, inflammation may result in dysregulation between elastin breakdown and production. Some elastolytic enzyme expressions i.e. matrix metalloproteinase-9, are induced by pro-inflammatory cytokines.[8]

Limitations
Our present study was limited by its cross-sectional design in nature. Other factors which might affect the association between lipid profiles or ratios and arterial stiffness, such as race-ethnicity, duration of diabetes, and medications (statins, antihypertensive, and antidiabetics), were not controlled for in this study; therefore, a bias is likely to be present.

Conclusions
Lipid profiles and lipid ratios, especially TG/HDL-C ratio and non-HDL-C, are potential biochemical markers for arterial stiffness in T2DM patients. Type 2 DM patients with arterial stiffness were likely to have elevated lipid profiles and lipid ratios. We recommend further research with a better design (cohort) and larger scale before applying these parameters in clinical practice.

Data availability
Underlying data
Figshare: Underlying data for 'The performance of lipid profiles and ratios as a predictor of arterial stiffness measured by brachial-ankle pulse wave velocity in type 2 diabetic patients'. https://doi.org/10.6084/m9.figshare.21572874.[17]

Reporting guidelines
Figshare: STROBE checklist for 'The performance of lipid profiles and ratios as a predictor of arterial stiffness measured by brachial-ankle pulse wave velocity in type 2 diabetic patients'. https://doi.org/10.6084/m9.figshare.21572874.[17]

References

1. Khan MAB, Hashim MJ, King JK, *et al.*: **Epidemiology of type 2 diabetes–global burden of disease and forecasted trends.** *J. Epidemiol. Glob. Health.* 2020 [cited 2022 Nov 8]; **10**(1): 107–111. **PubMed Abstract** | **Publisher Full Text** | **Free Full Text**

2. Saeedi P, Petersohn I, Salpea P, *et al.*: **Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas.** *Diabetes Res. Clin. Pract.* 2019 [cited 2022 Nov 8]; **157**: 107843. **PubMed Abstract** | **Publisher Full Text**

3. Litwak L, Goh SY, Hussein Z, *et al.*: **Prevalence of diabetes complications in people with type 2 diabetes mellitus and its association with baseline characteristics in the multinational A1chieve study.** *Diabetol. Metab. Syndr.* 2013 [cited 2022 Nov 8]; **5**(1): 1–10. **PubMed Abstract** | **Publisher Full Text** | **Free Full Text**

4. Einarson TR, Acs A, Ludwig C, *et al.*: **Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017.** *Cardiovasc. Diabetol.* 2018; **17**(1): 83. **PubMed Abstract** | **Publisher Full Text** | **Free Full Text**

5. Leon BM, Maddox TM: **Diabetes and cardiovascular disease: epidemiology, biological mechanisms, treatment recommendations and future research.** *World J. Diabetes.* 2015 [cited 2022 Nov 8]; **6**(13): 1246–1258. **PubMed Abstract** | **Publisher Full Text** | **Free Full Text**

6. Low Wang CC, Hess CN, Hiatt WR, *et al.*: **Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus–mechanisms, management, and clinical considerations.** *Circulation.* 2016 [cited 2022 Nov 8]; **133**(24): 2459–2502. **PubMed Abstract** | **Publisher Full Text** | **Free Full Text**

7. Pereira T: **Dyslipidemia and cardiovascular risk: lipid ratios as risk factors for cardiovascular disease.** *Dyslipidemia-From Prevention to Treatment.* 2012; **14**: 279–302. **Publisher Full Text**

8. Palombo C, Kozakova M: **Arterial stiffness, atherosclerosis and cardiovascular risk: Pathophysiologic mechanisms and emerging clinical indications.** *Vasc. Pharmacol.* 2016 [cited 2022 Nov 8]; **77**: 1–7. **PubMed Abstract** | **Publisher Full Text**

9. Zhao W, Gong W, Wu N, *et al.*: **Association of lipid profiles and the ratios with arterial stiffness in middle-aged and elderly Chinese.** *Lipids Health Dis.* 2014 [cited 2022 Nov 8]; **13**(1): 1–6. **PubMed Abstract** | **Publisher Full Text** | **Free Full Text**

10. Mancia G, Fagard R, Narkiewicz K, *et al.*: **2013 ESH/ESC practice guidelines for the management of arterial hypertension: ESH-ESC the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).** *Blood Press.* 2014 [cited 2022 Nov 8]; **23**(1): 3–16. **Publisher Full Text**

11. Tanaka H, Munakata M, Kawano Y, *et al.*: **Comparison between carotid-femoral and brachial-ankle pulse wave velocity as measures of arterial stiffness.** *J. Hypertens.* 2009 [cited 2022 Nov 8]; **27**(10): 2022–2027. **PubMed Abstract** | **Publisher Full Text**

12. Baier D, Teren A, Wirkner K, *et al.*: **Parameters of pulse wave velocity: determinants and reference values assessed in the population-based study LIFE-Adult.** *Clin. Res. Cardiol.* 2018 [cited 2022 Nov 8]; **107**(11): 1050–1061. **PubMed Abstract** | **Publisher Full Text** | **Free Full Text**

13. Dobrowolski P, Prejbisz A, Kuryłowicz A, *et al.*: **Metabolic syndrome – a new definition and management guidelines. A joint position paper by the Polish Society of Hypertension, Polish Society for the Treatment of Obesity, Polish Lipid Association, Polish Association for Study of Liver, Polish Society of Family Medicine, Polish Society of Lifestyle Medicine, Division of Prevention and Epidemiology Polish Cardiac Society, "Club 30" Polish Cardiac Society, and Division of Metabolic and Bariatric Surgery Society of Polish Surgeons.** *Arch. Med. Sci.* 2022 [cited 2023 May 31]; **18**(5): 1133–1156. **Publisher Full Text**

14. Artha IMJR, Bhargah A, Dharmawan NK, *et al.*: **High level of individual lipid profile and lipid ratio as a predictive marker of poor glycemic control in type-2 diabetes mellitus.** *Vasc. Health Risk Manag.* 2019; **15**: 149–157. **PubMed Abstract** | **Publisher Full Text** | **Free Full Text**

15. Townsend RR, Wilkinson IB, Schiffrin EL, *et al.*: **Recommendations for Improving and Standardizing Vascular Research on Arterial Stiffness.** *Hypertension.* 2015 [cited 2023 May 31]; **66**(3): 698–722. **Publisher Full Text**

16. Tomiyama H, Matsumoto C, Shiina K, *et al.*: **Brachial-ankle PWV: current status and future directions as a useful marker in the management of cardiovascular disease and/or cardiovascular risk factors.** *J. Atheroscler. Thromb.* 2016 [cited 2022 Nov 9]; **23**(2): 128–146. **Publisher Full Text**

17. Soelistijo SA, Adiwinoto RD, Pranoto A, *et al.*: Soelistijo2022_Lipid ratios & ba-PWV data.xlsx. [Dataset]. *figshare.* 2022. **Publisher Full Text**

18. Hansen L, Taylor WR: **Is increased arterial stiffness a cause or consequence of atherosclerosis?** *Atherosclerosis.* 2016 [cited 2022 Nov 12]; **249**: 226–227. **PubMed Abstract** | **Publisher Full Text** | **Free Full Text**

19. Kolluru GK, Bir SC, Kevil CG: **Endothelial Dysfunction and Diabetes: Effects on Angiogenesis, Vascular Remodeling, and Wound Healing. Calvert JW, editor.** *Int. J. Vasc. Med.* 2012; **2012**: 918267. **PubMed Abstract** | **Publisher Full Text** | **Free Full Text**

20. Warraich HJ, Rana JS: **Dyslipidemia in diabetes mellitus and cardiovascular disease.** *Cardiovasc. Endocrinol.* 2017 [cited 2022 Nov 12]; **6**(1): 27–32. **PubMed Abstract** | **Publisher Full Text** | **Free Full Text**

21. Chen C, Dai JL: **Triglyceride to high-density lipoprotein cholesterol (HDL-C) ratio and arterial stiffness in Japanese population: a secondary analysis based on a cross-sectional study.** *Lipids Health Dis.* 2018 [cited 2022 Nov 13]; **17**(1): 130–139. **PubMed Abstract** | **Publisher Full Text** | **Free Full Text**

22. Mulè G, Nardi E, Geraci G, *et al.*: **The relationships between lipid ratios and arterial stiffness.** *J. Clin. Hypertens.* 2017 [cited 2022 Nov 13]; **19**(8): 777–779. **PubMed Abstract** | **Publisher Full Text** | **Free Full Text**

23. Bando Y, Wakaguri H, Aoki K, *et al.*: **Non-high-density cholesterol level as a predictor of maximum carotid intima-media thickness in Japanese subjects with type 2 diabetes: a comparison with low-density lipoprotein level.** *Diabetol. Int.* 2016; **7**(1): 34–41. **PubMed Abstract** | **Publisher Full Text** | **Free Full Text**

24. de Oliveira AR, Mourao-Junior CA, Magalhães GL, *et al.*: **Non-HDL cholesterol is a good predictor of the risk of increased arterial stiffness in postmenopausal women in an urban Brazilian population.** *Clinics.* 2017 [cited 2022 Nov 13]; **72**: 106–110. **PubMed Abstract** | **Publisher Full Text** | **Free Full Text**

25. Virani SS: **Non-HDL cholesterol as a metric of good quality of care: opportunities and challenges.** *Tex. Heart Inst. J.* 2011; **38**(2): 160–162. **PubMed Abstract**

26. Nordestgaard BG: **Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology.** *Circ. Res.* 2016 [cited 2022 Nov 13]; **118**(4): 547–563. **Publisher Full Text**

27. Ardiany D, Pranoto A, Soelistijo SA, *et al.*: **Association between neutrophil–lymphocyte ratio on arterial stiffness in type-2 diabetes mellitus patients: a part of DiORS Study.** *Int. J. Diabetes Dev. Ctries.* 2022; **42**(2): 305–312. **Publisher Full Text**

Open Peer Review

Current Peer Review Status: ✔ ❓

Version 1

Reviewer Report 30 May 2023

❓

Agata Stanek (iD)

[1] Department and Clinic of Internal Medicine, Angiiology and Physical Medicine, Medical University of Silesia, Bytom, Poland
[2] Department and Clinic of Internal Medicine, Angiiology and Physical Medicine, Medical University of Silesia, Bytom, Poland

This study aimed to explore the correlation of lipid profiles and ratios with arterial stiffness, construct a predictive model for arterial stiffness in T2DM patients, and ultimately analyze the performance (sensitivity and specificity) of the lipid ratios to detect arterial stiffness in T2DM patients. This was a cross-sectional design study conducted in the Endocrinology and Diabetes outpatient clinic at the Dr. Soetomo General Academic Hospital in Surabaya, Indonesia, during February–May 2016 and September–November 2019.

It is quite an interesting paper. The Authors have presented sufficient data. The appropriate tables and figures have been provided. The article is easy to read and logically structured. The authors used appropriate statistical methods. The conclusions are consistent with the presented evidence and arguments.

The Authors should address the following issues:
1. How many patients have metabolic syndrome? We know that metabolic syndrome (MS) is not a single disease but a cluster of metabolic disorders associated with increased risk for the development of diabetes mellitus and its complications. Please discuss this issue and cite the newest papers in this field.

2. Please describe more precisely the measurement of arterial stiffness (according to which recommendations f.e. the measurement was carried out in appropriate conditions, such as, among others: a quiet, dry room, ensuring thermal comfort; moreover, the measurement should be carried out after a ten-minute rest in a lying position. The BP value and heart rate (HR) should also be taken into account during the interpretation of the PWV value, as these parameters can influence the PWV measurement result {doi: 10.1161/HYP.0000000000000033]

References

1. Townsend RR, Wilkinson IB, Schiffrin EL, Avolio AP, et al.: Recommendations for Improving and Standardizing Vascular Research on Arterial Stiffness: A Scientific Statement From the American Heart Association.*Hypertension*. 2015; **66** (3): 698-722 PubMed Abstract | Publisher Full Text

Is the work clearly and accurately presented and does it cite the current literature?
Partly

Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?
Yes

If applicable, is the statistical analysis and its interpretation appropriate?
Yes

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: vascular medicine, PAD, thromboembolism,

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Reviewer Report 16 May 2023

https://doi.org/10.5256/f1000research.141237.r169341

✔️ **Martin Haluzík**
[1] Diabetes Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
[2] Diabetes Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

Early identification of arterial stiffness in Type 2 diabetes mellitus (T2DM) patients before the signs

of overt atherosclerosis would be clinically beneficial. Current study aimed to explore the correlation of lipid profiles and ratios with arterial stiffness, and construct a predictive model for arterial stiffness in T2DM patients using those parameters. The study included one hundred and eighty-four adult T2DM patients in the diabetes outpatient clinic at the Dr. Soetomo general academic hospital in 2015 and 2019. Sociodemographic, glycosylated hemoglobin (HbA1c), lipid profiles, and brachial-ankle pulse wave velocity (ba-PWV) data were collected from all subjects. The subjects were divided into a group with arterial stiffness (ba-PWV > 18 m/sec) and without arterial stiffness (ba-PWV $\leq$ 18 m/sec). A correlation test was used to evaluate the association, and receiver operator characteristics (ROC) curves analysis were used to determine the cut-off value, sensitivity, and specificity. The risk analysis model was calculated using bivariate logistic regression analysis.

The group with arterial stiffness had higher lipid profiles: total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and lipid ratios. A significant positive correlation was found between TC, TG, LDL-C, and all lipid ratios with ba-PWV. A negative correlation was found between HDL-C and ba-PWV. All lipid ratio parameters can be used as predictors of arterial stiffness, especially non-HDL-C with cutoff value: 150 mg/dL (sensitivity 96.8% and specificity 52.9%) and TG/HDL-C ratio with cut-off value: 4.51 (sensitivity 81.0% and specificity 74.2%). Elevated TG/HDL-C ratio and non-HDL-C displayed higher risk (OR: 12.293 and 16.312; p < 0.05) of having arterial stiffness compared to other lipid ratios. Lipid profiles and lipid ratios, especially TG/HDL-C ratio and non-HDL-C, are potential biochemical markers for arterial stiffness in T2DM patients

This is an interesting study on a reasonable number of patients. The paper is well written and the results are appropriate.

I have only one minor comment: is there any reason why the authors included only lipids to their estimation. Why not include e.g. HbA1c and body weight as another important and easily obtainable parameters?

Is the work clearly and accurately presented and does it cite the current literature?
Yes

Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?
Yes

If applicable, is the statistical analysis and its interpretation appropriate?
Yes

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: diabetes, obesity, insulin resistance

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias

- You can publish traditional articles, null/negative results, case reports, data notes and more

- The peer review process is transparent and collaborative

- Your article is indexed in PubMed after passing peer review

- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research